Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial.

Background: To assess the immunogenicity and safety of two-dose regimen of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis (PTB) and explored the potential benefits of additional dose.

Research Design And Methods: In total, 182 PTB patients were randomly (1:1) assigned to the standard-dose group to receive three standard doses of inactivated COVID-19 vaccines, or the double-dose boosting group to receive two standard doses plus a double dose, with a 28-day interval. Forty healthy controls were assigned to receive two doses of inactivated COVID-19 vaccines 28 days apart.

lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis.

A growing number of dysregulated long non‑coding (lnc)RNAs have been verified to serve an essential role in human prostate cancer. However, the underlying mechanisms of lncRNA MNX1 Antisense RNA 1 (MNX1‑AS1) in prostate cancer has not been explored. Therefore, the present study aimed to explore the function of MNX1‑AS1 in prostate cancer tumorigenesis and investigate the in‑depth mechanism.

The association between interleukin-19 concentration and diabetic nephropathy.

Background: Interleukin-19 (IL-19) is a newly discovered cytokine belonging to the Interleukin-10(IL-10) family. IL-19 have indispensable functions in many inflammatory processes and also can induce the angiogenic potential of endothelial cells. The purpose of present study was to investigate the relation of serum interleukin-19 (IL-19) levels with diabetic nephropathy (DN).

Association between interleukin-19 and angiopoietin-2 with vascular complications in type 2 diabetes.

Aims/introduction: The aim of the present study was to investigate the role of interleukin-19 (IL-19) in angiogenesis of type 2 diabetes mellitus with complications, and to assess the relationship of serum IL-19 and angiopoietin-2 (Ang-2) in type 2 diabetes mellitus.

Materials And Methods: The group studied comprised of 240 patients with type 2 diabetes mellitus (132 men and 108 women), and included macrovascular complications, microvascular complications and type 2 diabetes mellitus without vascular complications. The control group consisted of 50 healthy blood donors.

Interleukin-19 and angiopoietin-2 can enhance angiogenesis of diabetic complications.

This study was to investigate the role of interleukin-19 (IL-19) and angiopoietin-2 (Ang-2) in angiogenesis of type 2 diabetes (T2DM). In 240 patients with T2DM, IL-19 and Ang-2 levels were higher, IL-19 was positively correlated with Ang-2. IL-19 and Ang-2 might be involved in angiogenesis of T2DM complications.